The scientific community has been captivated by the psychoactive effects of lysergic acid diethylamide (LSD), leading to the exploration of similar compounds to better understand their interactions at a molecular level and to discover potential new treatments. Various LSD analogues, such as 1-propionyl-LSD (1P–LSD), AL-LAD, and LSZ, have emerged in the market in different forms. However, the lack of analytical data for these new compounds poses a challenge for clinical and toxicological studies. Recently, two lysergamides, N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1P–ETH-LAD, were identified using advanced analytical techniques. While some information was available for ETH-LAD, data on 1P–ETH-LAD was scarce in scientific literature. This research contributes to the understanding of lysergamides available in the market, providing valuable information for healthcare professionals and researchers. Furthermore, a study on 1P–ETH-LAD revealed its potential as a pro-drug, as it was still present in serum after 24 hours of incubation with human serum at 37°C.